Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

证券代码：688068 证券简称：热景生物 公告编号：2026-003 北京热景生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/11/12 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 12 11 | 11 | 日~2026 | 年 | 月 | 11 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 904,054股 | | | | | | | | 累计已回购股数占总股本比例 | 0.98% | | | | | | | | 累计已回购金额 | 149,955,134.73元 | | | | | | ...

出售计划的进展情况 北京热景生物技术股份有限公司 关于出售已回购股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 公司于 2025 年 12 月 23 日召开第四届董事会第八次会议，审议并通过《关 于出售部分已回购股份的议案》，同意公司根据《关于以集中竞价交易方式回购 公司股份的回购报告书》（公告编号：2024-014）的约定，采用集中竞价交易方 式出售公司于 2024 年 2 月 8 日至 2024 年 5 月 7 日期间已回购的公司股份。公司 计划自披露出售已回购股份计划之日起 15 个交易日后的六个月内（2026 年 1 月 19 日至 2026 年 7 月 18 日），通过集中竞价交易方式出售已回购股份不超过 1,854,158 股。具体内容详见公司于 2025 年 12 月 24 日在上海证券交易所网站 （www.sse.com.cn）披露的《北京热景生物技术股份有限公司关于以集中竞价交 易方式出售部分已回购股份计划公告》（公告编号：2025-090）。 重要内容提示： 回购股份的基本情况 ...

Core Viewpoint - The company, 热景生物 (Hotgen Biotech), has conducted a share buyback, acquiring a total of 904,100 shares, which represents 0.98% of its total share capital of 92,707,900 shares [1] Group 1 - The share buyback was executed through a dedicated securities account via centralized bidding [1] - The highest price paid for the repurchased shares was 176.79 RMB per share, while the lowest price was 145.59 RMB per share [1] - The total amount spent on the share buyback was 150 million RMB, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company announced a share repurchase plan approved on November 11, 2025, aiming to buy back shares worth 100 to 200 million yuan for employee stock ownership plans or equity incentives, with a maximum price of 244 yuan per share, valid until November 11, 2026 [1] - As of January 31, 2026, the company has repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, with total funds paid amounting to 149,955,134.73 yuan, and the repurchase price range was between 145.59 and 176.79 yuan per share [1]

Summary of Key Points Core Viewpoint - The company, 热景生物 (Hotgen Biotech), has announced a share buyback program, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 904,000 shares, which represents 0.98% of its total share capital [1] - The highest price paid for the repurchased shares was 176.79 yuan per share, while the lowest price was 145.59 yuan per share [1] - The total amount spent on the share buyback was 150 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Hotgen Biotech (688068.SH), announced a share buyback program, having repurchased a total of 904,000 shares, which represents 0.98% of its total share capital [1] - The highest price paid for the repurchased shares was 176.79 yuan per share, while the lowest price was 145.59 yuan per share [1] - The total amount spent on the share buyback was 150 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - On February 2, 2023, Hotgen Biotech experienced a decline of 5.36% with a trading volume of 211 million yuan. The financing data indicated a net buying of 1.17 million yuan for the day, with a total financing and margin balance of 156 million yuan [1] - The financing balance of Hotgen Biotech was reported at 154 million yuan, accounting for 1.21% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low position [1] - In terms of securities lending, Hotgen Biotech had a securities lending balance of 2.27 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, 2023, Hotgen Biotech had 7,833 shareholders, an increase of 12.9% from the previous period. The average circulating shares per person decreased by 11.43% to 11,835 shares [2] - For the period from January to September 2023, Hotgen Biotech reported a revenue of 310 million yuan, a year-on-year decrease of 19.8%. The net profit attributable to the parent company was -109 million yuan, a significant decrease of 168.12% [2] - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.34 million yuan distributed over the past three years [3]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The core viewpoint of the news is that Beijing Hotgen Biotech Co., Ltd. has seen a stock price increase of 5.05%, reaching 154.89 yuan per share, with a total market capitalization of 14.36 billion yuan [1] - The company specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from others, and 1.17% from biological raw materials [1] - The stock trading volume for the day was 2.70 billion yuan, with a turnover rate of 1.92% [1] Group 2 - In terms of fund holdings, Invesco Great Wall Fund has a significant position in Hotgen Biotech, with its fund "Invesco Great Wall Emerging Industries Mixed A" holding 178,500 shares, accounting for 3.7% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a total scale of 487 million yuan and has achieved a year-to-date return of 2.75%, ranking 6142 out of 8861 in its category [2] - The fund manager, Nong Bingli, has been in position for 7 years and 222 days, with the best fund return during his tenure being 174.01% [3]